The Hand of God! Do u guys agree?

38 year old British photographer David Christie said he captured the stunning moment a gigantic 'hand' appeared through the clouds above his home...and he thinks the fist-like wind funnel is the 'Hand of God'. "I love weather photography and I've taken a few pictures of small wind funnels in the past. But this was something else. It looked as through there was a huge hand piercing through the clouds - it was phenomenal. It really did seem like the hand of God. My wife and I are both photographers and we've never seen anything like this. This was a very surreal experience." He told reporters

Breaking News: Wasiu Ayinde Attacked By Political Gunmen

King Wasiu Ayinde Marshal 1 is alive and thanking God. Please join him as you read how God thwarted the plans of the enemy concerning his life.Thank God for sparing the life of King Wasiu Ayinde Marshal who was shot at by unknown gun men as he drove himself on Sunday August 3, 2014 in Osun state.Sources say he attended a political rally and was on his way back whenit happened.KWAM1 is presently in shock and wondering why anyone would want him snuffed out.Thank God for his life.

Industry Nite With Runtown holds this Wednesday

Industry Nite & Eric Many Entertainment Present Industry Nite with RunTown this Wednesday August 6th 2014, at Spice Route on Adeola Odeku, Victoria Island, Lagos.  Experience a first of its kind Live performance by RunTown and Super Producer Pheelz with the maschine drum kit. This industry nite is tagged Flossing and Flawless and will Also feature performances from Davido, Phyno, Skales, Samad, Presh ,DJ switch and many more. Continue...Host : Jimmie. Official DJ : DJ spinall ...This Industry nite is proudly supported by Eric Many Entertainment, MCOMM, Bankulli Entertainment, The Beat 99.9FM, Smirnoff Ice, Pulseng and YSG Hubs

Fast finger 2. Glo Recharge pin

235894380930529. Who ever wins should plzzzz comment here on the blog.

Experimental drug likely saved Ebola patients

(CNN) -- Three vials containing an experimental drug stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment.The drug appears to have worked. Dr. Kent Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say. Brantly was able to walk into Emory University Hospital in Atlanta after being evacuated to the United States last week, and Writebol is expected to arrive in Atlanta on Tuesday.On July 22, Brantly woke up feeling feverish. Fearing the worst, Brantly immediately isolated himself. Writebol's symptoms started three days later. A rapid field blood test confirmed the infection in both of them after they had become ill with fever, vomiting and diarrhea.It's believed both Brantly and Writebol, who worked with the aid organization Samaritan's Purse, contracted Ebola from another health care worker at their hospital in Liberia, although the official Centers for Disease Control and Prevention case investigation has yet to be released.A representative from the National Institutes of Health contacted Samaritan's Purse in Liberia and offered the experimental treatment, known as ZMapp, for the two patients, according to the source.Photos: Ebola outbreak in West AfricaSecond Ebola patient heading to U.S.Doctors struggle to treat Ebola patientsEbola transport team speaks to CNNThe drug was developed by the biotech firm Mapp Biopharmaceutical Inc., which is based in San Diego. The patients were told that this treatment had never been tried before in a human being but had shown promise in small experiments with monkeys.Questions about this new Ebola drugAccording to company documents, four monkeys infected with Ebola survived after being given the therapy within 24 hours after infection. Two of four other monkeys that started therapy within 48 hours after infection also survived. One monkey that was not treated died within five days of exposure to the virus.Brantly and Writebol were aware of the risk of taking a new, little understood treatment and gave informed consent, according to two sources familiar with the care of the missionary workers. In the monkeys, the experimental serum had been given within 48 hours of infection. Brantly didn't receive it until he'd been sick for nine days.The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.The Ebola virus causes viral hemorrhagic fever, which refers to a group of viruses that affect multiple organ systems in the body and are often accompanied by bleeding.Early symptoms include sudden onset of fever, weakness, muscle pain, headaches and a sore throat. They later progress to vomiting, diarrhea, impaired kidney and liver function -- and sometimes internal and external bleeding.The ZMapp vials reached the hospital in Liberia where Brantly and Writebol were being treated Thursday morning. Doctors were instructed to allow the serum to thaw naturally without any additional heat. It was expected that it would be eight to 10 hours before the medicine could be given, according to a source familiar with the process.Brantly asked that Writebol be given the first dose because he was younger and he thought he had a better chance of fighting it, and she agreed. However, as the first vial was still thawing, Brantly's condition took a sudden turn for the worse.Brantly began to deteriorate and developed labored breathing. He told his doctors he thought he was dying, according to a source with firsthand knowledge of the situation.Knowing his dose was still frozen, Brantly asked if he could have Writebol's now-thawed medication. It was brought to his room and administered through an IV. Within an hour of receiving the medication, Brantly's condition dramatically improved. He began breathing easier; the rash over his trunk faded away. One of his doctors described the events as "miraculous."By the next morning, Brantly was able to take a shower on his own before getting on a specially designed Gulfstream air ambulance jet to be evacuated to the United States.Writebol also received a vial of the medication. Her response was not as remarkable, according to sources familiar with the treatment. However, doctors on Sunday administered Writebol a second dose of the medication, which resulted in significant improvement.She was stable enough to be evacuated back to the United States and is expected to arrive before noon Tuesday.The process by which the medication was made available to Brantly and Writebol is highly unusual. ZMapp has not been approved for human use, and has not even gone through the clinical trial process, which is standard to prove the safety and efficacy of a medication. It may have been given under the U.S. Food and Drug Administration's "compassionate use" regulation, which allows access to investigational drugs outside clinical trials.Getting approval for compassionate use is often long and laborious, but in the case of Brantly and Writebol, they received the medication within seven to 10 days of their exposure to the Ebola virus.On July 30, the Defense Threat Reduction Agency, an arm of the military responsible for any chemical, biological, radiological, nuclear and high-yield explosive threats, allotted additional fundingto MAPP Biopharmaceutical due to "promising results."

Experimental drug likely saved Ebola patients

(CNN) -- Three vials containing an experimental drug stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment.The drug appears to have worked. Dr. Kent Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say. Brantly was able to walk into Emory University Hospital in Atlanta after being evacuated to the United States last week, and Writebol is expected to arrive in Atlanta on Tuesday.On July 22, Brantly woke up feeling feverish. Fearing the worst, Brantly immediately isolated himself. Writebol's symptoms started three days later. A rapid field blood test confirmed the infection in both of them after they had become ill with fever, vomiting and diarrhea.It's believed both Brantly and Writebol, who worked with the aid organization Samaritan's Purse, contracted Ebola from another health care worker at their hospital in Liberia, although the official Centers for Disease Control and Prevention case investigation has yet to be released.A representative from the National Institutes of Health contacted Samaritan's Purse in Liberia and offered the experimental treatment, known as ZMapp, for the two patients, according to the source.Photos: Ebola outbreak in West AfricaSecond Ebola patient heading to U.S.Doctors struggle to treat Ebola patientsEbola transport team speaks to CNNThe drug was developed by the biotech firm Mapp Biopharmaceutical Inc., which is based in San Diego. The patients were told that this treatment had never been tried before in a human being but had shown promise in small experiments with monkeys.Questions about this new Ebola drugAccording to company documents, four monkeys infected with Ebola survived after being given the therapy within 24 hours after infection. Two of four other monkeys that started therapy within 48 hours after infection also survived. One monkey that was not treated died within five days of exposure to the virus.Brantly and Writebol were aware of the risk of taking a new, little understood treatment and gave informed consent, according to two sources familiar with the care of the missionary workers. In the monkeys, the experimental serum had been given within 48 hours of infection. Brantly didn't receive it until he'd been sick for nine days.The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.The Ebola virus causes viral hemorrhagic fever, which refers to a group of viruses that affect multiple organ systems in the body and are often accompanied by bleeding.Early symptoms include sudden onset of fever, weakness, muscle pain, headaches and a sore throat. They later progress to vomiting, diarrhea, impaired kidney and liver function -- and sometimes internal and external bleeding.The ZMapp vials reached the hospital in Liberia where Brantly and Writebol were being treated Thursday morning. Doctors were instructed to allow the serum to thaw naturally without any additional heat. It was expected that it would be eight to 10 hours before the medicine could be given, according to a source familiar with the process.Brantly asked that Writebol be given the first dose because he was younger and he thought he had a better chance of fighting it, and she agreed. However, as the first vial was still thawing, Brantly's condition took a sudden turn for the worse.Brantly began to deteriorate and developed labored breathing. He told his doctors he thought he was dying, according to a source with firsthand knowledge of the situation.Knowing his dose was still frozen, Brantly asked if he could have Writebol's now-thawed medication. It was brought to his room and administered through an IV. Within an hour of receiving the medication, Brantly's condition dramatically improved. He began breathing easier; the rash over his trunk faded away. One of his doctors described the events as "miraculous."By the next morning, Brantly was able to take a shower on his own before getting on a specially designed Gulfstream air ambulance jet to be evacuated to the United States.Writebol also received a vial of the medication. Her response was not as remarkable, according to sources familiar with the treatment. However, doctors on Sunday administered Writebol a second dose of the medication, which resulted in significant improvement.She was stable enough to be evacuated back to the United States and is expected to arrive before noon Tuesday.The process by which the medication was made available to Brantly and Writebol is highly unusual. ZMapp has not been approved for human use, and has not even gone through the clinical trial process, which is standard to prove the safety and efficacy of a medication. It may have been given under the U.S. Food and Drug Administration's "compassionate use" regulation, which allows access to investigational drugs outside clinical trials.Getting approval for compassionate use is often long and laborious, but in the case of Brantly and Writebol, they received the medication within seven to 10 days of their exposure to the Ebola virus.On July 30, the Defense Threat Reduction Agency, an arm of the military responsible for any chemical, biological, radiological, nuclear and high-yield explosive threats, allotted additional fundingto MAPP Biopharmaceutical due to "promising results."

Experimental drug likely saved Ebola patients

(CNN) -- Three vials containing an experimental drug stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment.The drug appears to have worked. Dr. Kent Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say. Brantly was able to walk into Emory University Hospital in Atlanta after being evacuated to the United States last week, and Writebol is expected to arrive in Atlanta on Tuesday.On July 22, Brantly woke up feeling feverish. Fearing the worst, Brantly immediately isolated himself. Writebol's symptoms started three days later. A rapid field blood test confirmed the infection in both of them after they had become ill with fever, vomiting and diarrhea.It's believed both Brantly and Writebol, who worked with the aid organization Samaritan's Purse, contracted Ebola from another health care worker at their hospital in Liberia, although the official Centers for Disease Control and Prevention case investigation has yet to be released.A representative from the National Institutes of Health contacted Samaritan's Purse in Liberia and offered the experimental treatment, known as ZMapp, for the two patients, according to the source.Photos: Ebola outbreak in West AfricaSecond Ebola patient heading to U.S.Doctors struggle to treat Ebola patientsEbola transport team speaks to CNNThe drug was developed by the biotech firm Mapp Biopharmaceutical Inc., which is based in San Diego. The patients were told that this treatment had never been tried before in a human being but had shown promise in small experiments with monkeys.Questions about this new Ebola drugAccording to company documents, four monkeys infected with Ebola survived after being given the therapy within 24 hours after infection. Two of four other monkeys that started therapy within 48 hours after infection also survived. One monkey that was not treated died within five days of exposure to the virus.Brantly and Writebol were aware of the risk of taking a new, little understood treatment and gave informed consent, according to two sources familiar with the care of the missionary workers. In the monkeys, the experimental serum had been given within 48 hours of infection. Brantly didn't receive it until he'd been sick for nine days.The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.The Ebola virus causes viral hemorrhagic fever, which refers to a group of viruses that affect multiple organ systems in the body and are often accompanied by bleeding.Early symptoms include sudden onset of fever, weakness, muscle pain, headaches and a sore throat. They later progress to vomiting, diarrhea, impaired kidney and liver function -- and sometimes internal and external bleeding.The ZMapp vials reached the hospital in Liberia where Brantly and Writebol were being treated Thursday morning. Doctors were instructed to allow the serum to thaw naturally without any additional heat. It was expected that it would be eight to 10 hours before the medicine could be given, according to a source familiar with the process.Brantly asked that Writebol be given the first dose because he was younger and he thought he had a better chance of fighting it, and she agreed. However, as the first vial was still thawing, Brantly's condition took a sudden turn for the worse.Brantly began to deteriorate and developed labored breathing. He told his doctors he thought he was dying, according to a source with firsthand knowledge of the situation.Knowing his dose was still frozen, Brantly asked if he could have Writebol's now-thawed medication. It was brought to his room and administered through an IV. Within an hour of receiving the medication, Brantly's condition dramatically improved. He began breathing easier; the rash over his trunk faded away. One of his doctors described the events as "miraculous."By the next morning, Brantly was able to take a shower on his own before getting on a specially designed Gulfstream air ambulance jet to be evacuated to the United States.Writebol also received a vial of the medication. Her response was not as remarkable, according to sources familiar with the treatment. However, doctors on Sunday administered Writebol a second dose of the medication, which resulted in significant improvement.She was stable enough to be evacuated back to the United States and is expected to arrive before noon Tuesday.The process by which the medication was made available to Brantly and Writebol is highly unusual. ZMapp has not been approved for human use, and has not even gone through the clinical trial process, which is standard to prove the safety and efficacy of a medication. It may have been given under the U.S. Food and Drug Administration's "compassionate use" regulation, which allows access to investigational drugs outside clinical trials.Getting approval for compassionate use is often long and laborious, but in the case of Brantly and Writebol, they received the medication within seven to 10 days of their exposure to the Ebola virus.On July 30, the Defense Threat Reduction Agency, an arm of the military responsible for any chemical, biological, radiological, nuclear and high-yield explosive threats, allotted additional fundingto MAPP Biopharmaceutical due to "promising results."

Experimental drug likely saved Ebola patients

(CNN) -- Three vials containing an experimental drug stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment.The drug appears to have worked. Dr. Kent Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say. Brantly was able to walk into Emory University Hospital in Atlanta after being evacuated to the United States last week, and Writebol is expected to arrive in Atlanta on Tuesday.On July 22, Brantly woke up feeling feverish. Fearing the worst, Brantly immediately isolated himself. Writebol's symptoms started three days later. A rapid field blood test confirmed the infection in both of them after they had become ill with fever, vomiting and diarrhea.It's believed both Brantly and Writebol, who worked with the aid organization Samaritan's Purse, contracted Ebola from another health care worker at their hospital in Liberia, although the official Centers for Disease Control and Prevention case investigation has yet to be released.A representative from the National Institutes of Health contacted Samaritan's Purse in Liberia and offered the experimental treatment, known as ZMapp, for the two patients, according to the source.Photos: Ebola outbreak in West AfricaSecond Ebola patient heading to U.S.Doctors struggle to treat Ebola patientsEbola transport team speaks to CNNThe drug was developed by the biotech firm Mapp Biopharmaceutical Inc., which is based in San Diego. The patients were told that this treatment had never been tried before in a human being but had shown promise in small experiments with monkeys.Questions about this new Ebola drugAccording to company documents, four monkeys infected with Ebola survived after being given the therapy within 24 hours after infection. Two of four other monkeys that started therapy within 48 hours after infection also survived. One monkey that was not treated died within five days of exposure to the virus.Brantly and Writebol were aware of the risk of taking a new, little understood treatment and gave informed consent, according to two sources familiar with the care of the missionary workers. In the monkeys, the experimental serum had been given within 48 hours of infection. Brantly didn't receive it until he'd been sick for nine days.The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.The Ebola virus causes viral hemorrhagic fever, which refers to a group of viruses that affect multiple organ systems in the body and are often accompanied by bleeding.Early symptoms include sudden onset of fever, weakness, muscle pain, headaches and a sore throat. They later progress to vomiting, diarrhea, impaired kidney and liver function -- and sometimes internal and external bleeding.The ZMapp vials reached the hospital in Liberia where Brantly and Writebol were being treated Thursday morning. Doctors were instructed to allow the serum to thaw naturally without any additional heat. It was expected that it would be eight to 10 hours before the medicine could be given, according to a source familiar with the process.Brantly asked that Writebol be given the first dose because he was younger and he thought he had a better chance of fighting it, and she agreed. However, as the first vial was still thawing, Brantly's condition took a sudden turn for the worse.Brantly began to deteriorate and developed labored breathing. He told his doctors he thought he was dying, according to a source with firsthand knowledge of the situation.Knowing his dose was still frozen, Brantly asked if he could have Writebol's now-thawed medication. It was brought to his room and administered through an IV. Within an hour of receiving the medication, Brantly's condition dramatically improved. He began breathing easier; the rash over his trunk faded away. One of his doctors described the events as "miraculous."By the next morning, Brantly was able to take a shower on his own before getting on a specially designed Gulfstream air ambulance jet to be evacuated to the United States.Writebol also received a vial of the medication. Her response was not as remarkable, according to sources familiar with the treatment. However, doctors on Sunday administered Writebol a second dose of the medication, which resulted in significant improvement.She was stable enough to be evacuated back to the United States and is expected to arrive before noon Tuesday.The process by which the medication was made available to Brantly and Writebol is highly unusual. ZMapp has not been approved for human use, and has not even gone through the clinical trial process, which is standard to prove the safety and efficacy of a medication. It may have been given under the U.S. Food and Drug Administration's "compassionate use" regulation, which allows access to investigational drugs outside clinical trials.Getting approval for compassionate use is often long and laborious, but in the case of Brantly and Writebol, they received the medication within seven to 10 days of their exposure to the Ebola virus.On July 30, the Defense Threat Reduction Agency, an arm of the military responsible for any chemical, biological, radiological, nuclear and high-yield explosive threats, allotted additional fundingto MAPP Biopharmaceutical due to "promising results."

Experimental drug likely saved Ebola patients

(CNN) -- Three vials containing an experimental drug stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment.The drug appears to have worked. Dr. Kent Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say. Brantly was able to walk into Emory University Hospital in Atlanta after being evacuated to the United States last week, and Writebol is expected to arrive in Atlanta on Tuesday.On July 22, Brantly woke up feeling feverish. Fearing the worst, Brantly immediately isolated himself. Writebol's symptoms started three days later. A rapid field blood test confirmed the infection in both of them after they had become ill with fever, vomiting and diarrhea.It's believed both Brantly and Writebol, who worked with the aid organization Samaritan's Purse, contracted Ebola from another health care worker at their hospital in Liberia, although the official Centers for Disease Control and Prevention case investigation has yet to be released.A representative from the National Institutes of Health contacted Samaritan's Purse in Liberia and offered the experimental treatment, known as ZMapp, for the two patients, according to the source.Photos: Ebola outbreak in West AfricaSecond Ebola patient heading to U.S.Doctors struggle to treat Ebola patientsEbola transport team speaks to CNNThe drug was developed by the biotech firm Mapp Biopharmaceutical Inc., which is based in San Diego. The patients were told that this treatment had never been tried before in a human being but had shown promise in small experiments with monkeys.Questions about this new Ebola drugAccording to company documents, four monkeys infected with Ebola survived after being given the therapy within 24 hours after infection. Two of four other monkeys that started therapy within 48 hours after infection also survived. One monkey that was not treated died within five days of exposure to the virus.Brantly and Writebol were aware of the risk of taking a new, little understood treatment and gave informed consent, according to two sources familiar with the care of the missionary workers. In the monkeys, the experimental serum had been given within 48 hours of infection. Brantly didn't receive it until he'd been sick for nine days.The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.The Ebola virus causes viral hemorrhagic fever, which refers to a group of viruses that affect multiple organ systems in the body and are often accompanied by bleeding.Early symptoms include sudden onset of fever, weakness, muscle pain, headaches and a sore throat. They later progress to vomiting, diarrhea, impaired kidney and liver function -- and sometimes internal and external bleeding.The ZMapp vials reached the hospital in Liberia where Brantly and Writebol were being treated Thursday morning. Doctors were instructed to allow the serum to thaw naturally without any additional heat. It was expected that it would be eight to 10 hours before the medicine could be given, according to a source familiar with the process.Brantly asked that Writebol be given the first dose because he was younger and he thought he had a better chance of fighting it, and she agreed. However, as the first vial was still thawing, Brantly's condition took a sudden turn for the worse.Brantly began to deteriorate and developed labored breathing. He told his doctors he thought he was dying, according to a source with firsthand knowledge of the situation.Knowing his dose was still frozen, Brantly asked if he could have Writebol's now-thawed medication. It was brought to his room and administered through an IV. Within an hour of receiving the medication, Brantly's condition dramatically improved. He began breathing easier; the rash over his trunk faded away. One of his doctors described the events as "miraculous."By the next morning, Brantly was able to take a shower on his own before getting on a specially designed Gulfstream air ambulance jet to be evacuated to the United States.Writebol also received a vial of the medication. Her response was not as remarkable, according to sources familiar with the treatment. However, doctors on Sunday administered Writebol a second dose of the medication, which resulted in significant improvement.She was stable enough to be evacuated back to the United States and is expected to arrive before noon Tuesday.The process by which the medication was made available to Brantly and Writebol is highly unusual. ZMapp has not been approved for human use, and has not even gone through the clinical trial process, which is standard to prove the safety and efficacy of a medication. It may have been given under the U.S. Food and Drug Administration's "compassionate use" regulation, which allows access to investigational drugs outside clinical trials.Getting approval for compassionate use is often long and laborious, but in the case of Brantly and Writebol, they received the medication within seven to 10 days of their exposure to the Ebola virus.On July 30, the Defense Threat Reduction Agency, an arm of the military responsible for any chemical, biological, radiological, nuclear and high-yield explosive threats, allotted additional fundingto MAPP Biopharmaceutical due to "promising results."

Fast finger! Mtn recharge pin. Let the fun begin

010078099546
Who ever loads it shoulf plz drop a comment on this blog so that people will know its real.

What a tragedy, fast rising singer Bbee dies at 30

Bbee was born into the of family Eruoghos from Ughelli North LGA of Delta. She has a background in Economics from the Lagos State University. Bbee discovered her love for singing as a little child in the church choir, afterward she moved into the adult choir even as a little girl and was referred to as "golden voice" because she was that unique. Music grew in her, which led her in joining a singing band in high school.She has a special way of singing her school's anthem, that gave her several recognition and award from the school authority. Upon graduation, she pursued her love for music, singing as backup singer with great Nigeria artists such as Onyeka Onwenu, Sammy Okposo, and Stella Damasus. She was once in the top 20 of the very first Nigeria Idol. Came as a 1st Runner up of the only Sony Ericsson singing competition and moved to form her own band, that played  in Sheraton Hotel and Towers for several years. Bbee in a bid to take her music career to the center stage Signed a management deal with  Music video director PRODIGY and in the 2nd week of May, she left for the USA to complete her latest single titled "Tif My Heart" Download Link
The song was due for release and it's Video billed to be Directed in the US by PRODIGY but was abruptly pushed forward due to Bbee's ill-health. Unfortunately she lost the fight for life on the 27th of July 2014.Vibrant Bbee lived a kind and humble life giving a helping hand to everyone that came her way. She left behind a legacy that will forever live on in our hearts, may her gentle soul rest in perfect peace... Amen.

Warning, Nigerian Doctor Who Attended To Liberian Man Comes Down With Ebola Virus In Lagos

Minister of Health, Professor Onyebuchi Chukwu, has just confirmed that one of the doctors who attended to Patrick Sawyer, the Liberian, who recently died of Ebola in Nigeria, is now sick with the disease.Chukwu said two other people placed under quarantine were showing signs of the disease, although it is too early to say if their symptoms relates to Ebola.Sawyer was Nigeria’s first case of Ebola death two weeks ago, and since his demise there have been widespread fears  that some of the more than 70 people he had contact with also develop the virus.

Nigerian celebs at the White House

A few Nigerian celebs including D'banj, Omawumi, Femi Kuti, Cobham Asuquo, his wife, Victoria Kimani and other African celebs are currently in the US to attend the 2014 Young African Leadership Initiative summit in Washington D.C.

Lagos Govt warns TB Joshua not to accept Ebola victims in his church

The Lagos state government has warned pastor TB Joshua of Synagogue Church of All Nations not to accept Ebola victims if they come to him for healing.According to The Nation officials of Lagos State Ministry of Health and the Federal Government, led by the Lagos State Commissioner for Health, Dr. Jide Idris, visited him seeking his cooperation in ensuring victims of the deadly virus are not brought to his church for healing. Synagogue is a popular destination for sick people who go there for divine healing. "We have our strategies that we intend to share with you. Again, we need to know the resources you have here because whether it is one or two cases, if they are allowed to get out, it is a major problem. We are here to work together on how to contain this disease,” Idris told the cleric." Dr Idris reportedly told Joshua. Continue...The commissioner added that the visit is one of the state government’s strategies of sensitizing faith-based organizations on the need to cooperate with the government to prevent the spread of the disease in the country by educating the worshipers to report health issues to medical experts.Idris said the Federal and Lagos state government are working hard to prevent a spread of the virus into the country, the delegation has deemed it fit to educate and create awareness among the multinational congregation on the disease and how it can spread.“We are here to engage you positively, we know the powers of this House and your powers and we are duty- bound to protect you and your congregation. We have no doubt the power God has given you, we can’t do that, but we want to help and make it work stronger,” Director, Centre for Disease Control (CDC), Professor Abdulsalami Nasidi, another member of the congregation told the prophet

FINALLY! Fashola Reacts To Ebola Virus Outbreak

Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever first appeared in 1976 and since then has terrorized the west African region for some time now but until case of Patrick Sawyer, a Liberian government official who died of the fatal disease at the First Consultant Medical Center in Obalende, Lagos there had been reported cases of Ebola in Nigeria.Shockingly  two weeks after the incident occurred  Governor of Lagos state – Babatunde Raji Fashola remained silent on w

hat has caused panic among Lagosians and Nigerians alike until now.Fashola on Friday at Lagos House, Ikeja, said Ebola was no longer a local problem, but an international one that required urgent measures in place to prevent its spread, urging the Federal Government to shut down its borders with affected West African countries to prevent outbreak of Ebola virus in the country.He said, “This is because it is easily transmittable across the borders and boundaries. The Federal Government team has been working with the state’s team. But I think what the Federal Government should do is to consider closing down some of our borders. It is difficult to stop this epidemic and we must now choose the treaty obligations that we hold under the ECOWAS treaty and perhaps short term benefits in terms of economic cost to human life. We must make that choice and consider it very seriously.”“It is a national security issue and I think that we should give it that attention. I think that men and women who man our border posts – sea, air and land – especially the customs, now know that they are our first line of defence. It is prevention, rather than calling the health professionals to quarantine people, that is really the strongest defence against the virus.”Fashola said the cremation of the remains of the Ebola victim in Lagos was the best option as dead bodies emitted fluid. The governor added that all residents who had contacts with the dead Liberian had been tested and that the result proved negative. But there is still risk because we heard that a dead body was brought into the country from Liberia. This means that there is still need for vigilance at our border post. The officials at these places should act professionally and report every incident they suspect,” Fashola added.while In related news, the commissioner for Health Dr Jide Idris has stated that two persons out of those who had contacts with the dead Liberian Ebola victim had manifested symptoms of fever.dris said the two persons were among the 70 contacts being monitored and investigated for any symptoms of the disease by the state government and other partners.The commissioner, who said the two cases were under observation, however stressed that they did not test positive to the virus.Idris said the state government would continue to monitor all contacts with the victims until the end of the 21 incubation day period of the virus.“Our Rapid Response Team is currently tracking all contacts of persons exposed to the dead passenger with Ebola virus.“The contract tracing team is following 70 contacts of the EVD case and linking them to clinical support when needed.“Two suspect cases had fever, they are under observation and so far have tested negative to the virus.“The monitoring of suspect cases will continue until the end of the period of 21 days from their exposure to the victim,’’ he said.